Heart & Circulation

Do you or someone you know well been affected by symptomatic hypertrophic cardiomyopathy? Your input is needed on a protocol considering Mavacamten vs Aficamten for people with symptomatic hypertrophic cardiomyopathy.

Skills / interests: Patient and public input

I am looking for a consumer who would be willing to provide feedback for a Cochrane protocol, “Mavacamten vs Aficamten for symptomatic hypertrophic cardiomyopathy”. Cochrane considers a consumer to be a person with experience of the condition (in this case, symptomatic hypertrophic cardiomyopathy), either as a patient or as a carer/family member of a patient. 

A protocol is a plan for a systematic review. Consumer input at protocol stage is integral to ensure that the completed systematic review will be helpful to patients and carers with healthcare decision making. For consumer peer review, you will be asked to complete a short form with your feedback. Our aim is for this to be a manageable task, that does not overburden consumer reviewers.   

 

Thank you in advance for considering! 

Ideal applicant

a person with experience of the condition (in this case, symptomatic hypertrophic cardiomyopathy)

Think you've got what it takes to get the job done for Lisa?

Log in
to respond

Questions & comments